UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/576,932	10/19/2006	Deborah Lynn Baly	05-936-A5	9105	
	20306 7590 07/13/2009 MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP			EXAMINER	
300 S. WACKER DRIVE			KUMAR, SHAILENDRA		
32ND FLOOR CHICAGO, IL 60606			ART UNIT	PAPER NUMBER	
			1621		
			MAIL DATE	DELIVERY MODE	
			07/13/2009	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/576,932	BALY ET AL.				
Office Action Summary	Examiner	Art Unit				
	SHAILENDRA KUMAR	1621				
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address				
Period for Reply	( IO OFT TO EVEIDE ( MONTH)	0) 0D THIRTY (00) BANG				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 19 O	ctober 2006.					
	action is non-final.					
3) Since this application is in condition for allowar						
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.				
Disposition of Claims						
4)⊠ Claim(s) <u>1-31</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)☐ Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-31</u> are subject to restriction and/or e	election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)  1) Notice of References Cited (RTO 903)	4) Intomious Comment	(PTO 442)				
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> </ol>	4)	ate				
3) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal P	atent Application				
Paper No(s)/Mail Date	6)					

Art Unit: 1621

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-14 and 23-25(in part), drawn to compounds, composition and metabolites of formula II of claim 2, when Z is non heterocyclic ring.

Group III, claim(s) 1-14 and 23-25(in part), drawn to compounds, composition and metabolites of formula II of claim 2, when Z is heterocyclic ring.

Group III, claim(s) 1-6, and 23-25(in part) drawn to compounds, composition and metabolites of formula III of claim 2.

Group IV, claim(s) 1-6 and 23-25(in part), drawn to compounds, composition and metabolites of formula IV of claim 2, when E is CH2.

Group V, claim(s) 1-6 and 23-25(in part), drawn to compounds, composition and metabolites of formula IV of claim 2, when E is S or O.

Group VI, claim(s) 1-6 and 23-25(in part), drawn to drawn to compounds, composition and metabolites of formula IV of claim 2, when E is N.

Group VII, claim(s) 1-6 and 23-25(in part), drawn to drawn to compounds, composition and metabolites of formula V of claim 2, when E is CH2.

Group VIII, claim(s) 1-6 and 23-25(in part), drawn to drawn to compounds, composition and metabolites of formula V of claim 2, when E is S or O.

Group IX, claim(s) 1-6 and 23-25(in part), drawn to drawn to compounds, composition and metabolites of formula V of claim 2, when E is N.

Group X, claim(s) 15-23(in part), drawn to compounds when X and Y are O.

Group XI, claim(s) 15-23(in part), drawn to when X and Y are N.

Group XII, claim(s) 26-28, drawn to method of modulating the in-vitro activity.

Group XIII, claim(s) 29, drawn to method of treating.

Group IXV, claim(s) 30, drawn to method of screening.

Group XV, claim(s) 31, drawn to method of inhibiting proliferative activity.

- 2. The inventions listed as Groups I-XV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Compounds of various groups are divergent and chemically disparate. Likewise the method claims are drawn to various method of treatment which are distinct from one another, thus lacking the same or corresponding technical feature.
- 3. In view of the complex nature of the restriction requirement, a written restriction requirement has been made.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Additionally, applicants need to elect a single disclosed species for the examination purposes. Claims will be examined to the extent claims read on the elected species and closely related compounds.

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Art Unit: 1621

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Page 4

5. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Application/Control Number: 10/576,932 Page 5

Art Unit: 1621

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHAILENDRA -. KUMAR whose telephone number is (571)272-0640. The examiner can normally be reached on Mon-Thur 8:00-5:30, Alt Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Daniel Sullivan can be reached on (571)272-0779. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/SHAILENDRA - KUMAR/ Primary Examiner, Art Unit 1621

S. Kumar 7/10/09